Aurobindo Pharma gets USFDA nod for Levofloxacin Injection

25 Jan 2013 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Levofloxacin Injection, 25mg/mL, packaged in 500mg/20mL and 750mg/30mL Single-use Vials.

Levofloxacin Injection, 25mg/mL packaged in 500mg/20mL and 750mg/30mL Single-use Vials is the generic equivalent of Janssen Pharmaceuticals Inc.’s Levaquin Injection 25mg/mL and indicated for the treatment of adults with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms such as Pneumonia. Acute Bacterial Sinusitis or Complicated Urinary Tract Infections etc and intravenous administration offers a route of administration advantageous to the patient. 

These ANDAs have been approved out of Unit IV formulation facility in Hyderabad, India for manufacturing general liquid injectable and ophthalmic products and will be marketed and sold by Aurobindo's US subsidiary AuroMedics Pharma LLC.

Aurobindo now has a total of 175 ANDA approvals (150 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1217.45 -6.20 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×